December 03, 2024
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Highly encouraging preclinical data highlight the possibility of lifelong treatment from a single administration of AVG-002 with preparations for clinical...
Continue Reading
April 14, 2023
Researchers have found a promising new method for delivering oxygen to tissues damaged by disease by coupling nitric oxide, which dilates blood vessels, with the oxygen carrying molecule hemoglobin to help people living with a number of diseases. Continue Reading
April 12, 2023
Harrington Scholar Dr. Khvorova and research team have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease. Continue Reading
April 10, 2023
Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading
April 03, 2023
Focus on glymphatic clearance, neurovascular health, and other novel approaches Continue Reading
March 07, 2023
2023 Harrington Prize for Innovation in Medicine Recognizes Pioneering Work in Retinal Gene Therapy for Genetic Diseases Continue Reading
March 01, 2023
Newfound clarity on the longstanding “medical mystery” may lead to new line of drugs for oxygen delivery disorders, including peripheral artery disease, sickle cell disease, heart failure, and others Continue Reading
February 23, 2023
UVA Health School of Medicine scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss. Continue Reading
February 14, 2023
Studies published from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments. Continue Reading
February 14, 2023
Thylacine Biotherapeutics Inc. entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform. Continue Reading
February 10, 2023
Investigators discovered that a specific complex drives cell proliferation in different forms of blood cancers called mutated myeloproliferative neoplasms (MPNs), suggesting the complex could serve as an ideal therapeutic target for blood cancer. Continue Reading